The IFI30 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population generated from the A-549 human lung adenocarcinoma cell line. This heterogeneous pool of cells harbors targeted disruptions in the IFI30 gene, creating a loss-of-function model ideal for studying lysosomal thiol reductase-mediated processes. The polyclonal format ensures consistent knockout effects while avoiding the genotypic drift often associated with single-cell clones. This product serves as a reliable tool for interrogating IFI30-dependent antigen processing without concerns about clonal artifacts.
The A-549 host cell line originates from human alveolar basal epithelium and is widely used as a type II pneumocyte model. These adherent epithelial cells exhibit characteristic cytokeratin expression and cytokine responsiveness, making them particularly relevant for studies of lung adenocarcinoma biology. Their ability to upregulate MHC class II molecules upon interferon gamma stimulation renders them an excellent platform for investigating antigen presentation pathways in a pulmonary epithelial context.
IFI30 encodes a lysosomal thiol reductase that reduces disulfide bonds in endocytosed antigens, enabling their unfolding and proteolytic processing by cathepsins. Its expression is induced by interferon gamma (IFNG) through STAT1 signaling. IFI30 interacts with MHC class II ???? dimers and the invariant chain CD74 to facilitate the generation of reduced peptide ligands. These peptides are loaded onto MHC class II with the help of HLA-DM and presented to CD4+ T cells. Knockout of IFI30 disrupts this reduction step, impairing peptide loading and attenuating CD4+ T cell responses.
In the A-549 adenocarcinoma background, IFI30 knockout mimics defects in MHC class II presentation that cancer cells exploit to evade immune surveillance. This model allows dissection of how IFNG/STAT1 signaling restores antigen processing and how IFI30 deficiency alters the peptide repertoire displayed on tumor cells. Because A-549 cells retain key epithelial characteristics, the knockouts also enable investigation of the crosstalk between epithelial cell biology and immune recognition in the tumor microenvironment.
These polyclonal knockout cells are suited for western blotting and RT-qPCR to verify IFI30 ablation and assess downstream pathway changes. Flow cytometry can measure surface MHC class II (HLA-DR, -DQ, -DP) levels after IFNG stimulation, while antigen presentation assays probe CD4+ T cell activation. Additional applications include immunofluorescence for endosomal localization and RNA sequencing for global transcriptomic profiling. For further information, please contact Ascent Research.
